Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Heavy Menstrual Bleeding
Uterine Fibroids

Interventions

DRUG: Elagolix
DRUG: Estradiol /norethindrone acetate (E2/NETA)
OTHER: E2/NETA Placebo
OTHER: Elagolix Placebo

Sponsor

AbbVie